Vioxx Sparks Debate over Malpractice Reform
Following the recent removal of the drug Vioxx from the market, lawmakers are reconsidering a portion of medical malpractice reform. Caps in the malpractice bill would affect pharmaceutical and medical product manufacturers. Democrats oppose the caps, but Sen. Orrin Hatch (R-UT) calls the situation a "feeding frenzy" for trial lawyers. NPR's Julie Rovner reports.
Copyright 2004 NPR